ArticleCancer cell2024
A road map for the treatment of pediatric diffuse midline glioma.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 18 citations in OpenAlex.
- Clinical, surgical, and molecular characteristics and outcomes of adult patients with diffuse midline glioma, H3 K27-altered, treated with surgical resection.Journal of neuro-oncology · 2026Article
- Microglia in diffuse midline glioma contribute to extracellular matrix remodelling and cancer cell invasion.Cell death & disease · 2026Article
- H3 dopaminylation and CaMKII modulate diffuse midline glioma response to CDK9 inhibition.bioRxiv : the preprint server for biology · 2026Article
- Deciphering the tumor microenvironment and role of immunotherapy in diffuse midline glioma: A scoping review.Neuro-oncology · 2026Article
- A bibliometric analysis of progress and trends in pediatric glioma research.Discover oncology · 2026Article
- Radiotherapy plus neoadjuvant and concomitant IL-13Rα2-directed immunotoxin therapy for diffuse intrinsic pontine glioma.Communications biology · 2026Article
- Diffuse midline glioma, H3K27-altered: a rare presentation with gliomatosis cerebri growth pattern and progression toward midline.Brain tumor pathology · 2026Article
- Pharmacological targeting and characterization of Voltage-Gated Sodium Channels (VGSCs) expressed in the high-grade glioma microenvironment.BMC cancer · 2025Article
- AI-augmented intraoperative decision-making workflows in diffuse midline glioma biopsy using cryosection pathology.Nature communications · 2025Article
- Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM.Acta neuropathologica · 2025Article
- Co-detection of mutations and methylations in cerebrospinal fluid ctdna for minimally-invasive diagnosis of brainstem glioma.Journal of experimental & clinical cancer research : CR · 2025Article
- Article
- Unlocking the secret of glioblastoma multiforme: the role of lactylation in tumor progression, drug resistance and immune microenvironment.Cancer cell international · 2025Article
- Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.Cell reports. Medicine · 2025Article
- Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- Multi-omics approaches reveal that diffuse midline gliomas present altered DNA replication and are susceptible to replication stress therapy.Genome biology · 2024Article
- Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.Cancer letters · 2024Review
- Understanding the mechanisms of diffuse midline glioma cell migration toward therapeutic targeting.Neuro-oncology · 2024Article
- Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG Registry.Neuro-oncology advancesArticle
- H3K27M-altered diffuse midline glioma: Experience and outcomes from a low-middle income country setting in the contemporary era.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
75 authors at 20 institutions in 8 countries.
Carl KoschmannUniversity of Michigan, Ann Arbor, MI 48109, USA. Electronic address: ckoschma@med.umich.edu.
Wajd N Al-HolouUniversity of Michigan, Ann Arbor, MI 48109, USA.
Marta M AlonsoClinica Universidad de Navarra, Navarra, Spain.
Jamie AnastasBaylor College of Medicine, Houston, TX 77030, USA.
Pratiti BandopadhayayDana-Faber Cancer Institute, Boston, MA 02215, USA.
Tara BarronStanford University, Stanford, CA 94305, USA.
Oren BecherIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Rodrigo CartaxoUniversity of Michigan, Ann Arbor, MI 48109, USA.
Maria G CastroUniversity of Michigan, Ann Arbor, MI 48109, USA.
Chan ChungDaegu Gyeongbuk Institute of Science & Technology, Daegu, South Korea.
Madison ClausenUniversity of Michigan, Ann Arbor, MI 48109, USA.
Derek DangUniversity of Michigan, Ann Arbor, MI 48109, USA.
Robert DohertyUniversity of Michigan, Ann Arbor, MI 48109, USA.
Ryan DuchatelUniversity of Newcastle, Callaghan, NSW 2308, Australia.
Matthew DunUniversity of Newcastle, Callaghan, NSW 2308, Australia.
Mariella FilbinDana-Faber Cancer Institute, Boston, MA 02215, USA.
Andrea FransonUniversity of Michigan, Ann Arbor, MI 48109, USA.
Stefanie GalbanUniversity of Michigan, Ann Arbor, MI 48109, USA.
Marc Garcia MoureClinica Universidad de Navarra, Navarra, Spain.
Hugh GartonUniversity of Michigan, Ann Arbor, MI 48109, USA.
Pruthvi GowdaDana-Faber Cancer Institute, Boston, MA 02215, USA.
Joana Graca MarquesClinica Universidad de Navarra, Navarra, Spain.
Cynthia HawkinsHospital for Sick Children, Toronto, ON M5G 1E8, Canada.
Allison HeathChildren's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Esther HullemanPrincess Maxima Center, 3584 CS Utrecht, the Netherlands.
Sunjong JiUniversity of Michigan, Ann Arbor, MI 48109, USA.
Chris JonesDivision of Molecular Pathology, Institute for Cancer Research, London SM2 5NG, UK.
Lindsay KilburnChildren's National, Washington, DC 20010, USA.
Cassie KlineChildren's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Michael A KoldobskiyJohn Hopkins University, Baltimore, MD 21205, USA.
Daniel LimUniversity of California, San Francisco, San Francisco, CA 94143, USA.
Pedro R LowensteinUniversity of Michigan, Ann Arbor, MI 48109, USA.
Q Richard LuCincinnati Children's Hospital Medical Center, and University of Cincinnati, Cincinnati, OH 45229, USA.
Joanna LumUniversity of Michigan, Ann Arbor, MI 48109, USA.
Stephen MackSt. Jude, Memphis, TN 38105, USA.
Suresh MaggeUniversity of Michigan, Ann Arbor, MI 48109, USA.
Bernard MariniUniversity of Michigan, Ann Arbor, MI 48109, USA.
Donna MartinUniversity of Michigan, Ann Arbor, MI 48109, USA.
Neena MarupudiUniversity of Michigan, Ann Arbor, MI 48109, USA.
Dana MessingerUniversity of Michigan, Ann Arbor, MI 48109, USA.
Rajen ModyUniversity of Michigan, Ann Arbor, MI 48109, USA.
Meredith MorganUniversity of Michigan, Ann Arbor, MI 48109, USA.
Mateus MotaUniversity of Michigan, Ann Arbor, MI 48109, USA.
Karin MuraszkoUniversity of Michigan, Ann Arbor, MI 48109, USA.
Sabine MuellerUniversity of California, San Francisco, San Francisco, CA 94143, USA; Parker Institute for Cancer Immunotherapy, University of Zurich, Zurich, Switzerland.
Siva Kumar NatarajanUniversity of Michigan, Ann Arbor, MI 48109, USA.
Javad NazarianChildren's National, Washington, DC 20010, USA; University of Zurich, Zurich, Switzerland.
Michael NiculceaUniversity of Michigan, Ann Arbor, MI 48109, USA.
Nicholas NuechterleinUniversity of Michigan, Ann Arbor, MI 48109, USA; National Institutes of Health, Bethesda, MD, USA.
Hideho OkadaUniversity of California, San Francisco, San Francisco, CA 94143, USA.
Valerie OpipariUniversity of Michigan, Ann Arbor, MI 48109, USA.
Manjunath P PaiUniversity of Michigan, Ann Arbor, MI 48109, USA.
Sharmistha PalDana-Faber Cancer Institute, Boston, MA 02215, USA.
Erik PetersonUniversity of Michigan, Ann Arbor, MI 48109, USA.
Timothy PhoenixCincinnati Children's Hospital Medical Center, and University of Cincinnati, Cincinnati, OH 45229, USA.
John R PrensnerUniversity of Michigan, Ann Arbor, MI 48109, USA.
Matthew PunUniversity of Michigan, Ann Arbor, MI 48109, USA.
G Praveen RajuIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Zachary J ReitmanDuke Univesity, Durham, NC 27708, USA.
Adam ResnickChildren's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
David RogawskiStanford University, Stanford, CA 94305, USA.
Amanda SaratsisAdvocate Children's Hospital, Park Ridge, IL 60068, USA.
Stefanie G SbergioHospital for Sick Children, Toronto, ON M5G 1E8, Canada.
Mark SouweidaneWeill Cornell Medicine, New York Presbyterian and Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
James M StaffordWeill Cornell Medicine, New York Presbyterian and Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Theophilos TzaridisHerbert Irving Comprehensive Cancer Center and Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA.
Sujatha VenkataramanUniversity of Colorado, Denver, CO 80204, USA.
Orazio VittorioSchool of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
Jack WaddenUniversity of Michigan, Ann Arbor, MI 48109, USA.
Daniel WahlUniversity of Michigan, Ann Arbor, MI 48109, USA.
Robert J Wechsler-ReyaSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Viveka Nand YadavChildren's Mercy, Kansas City, MO 64108, USA.
Xu ZhangSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Qiang ZhangUniversity of Michigan, Ann Arbor, MI 48109, USA.
Sriram VennetiUniversity of Michigan, Ann Arbor, MI 48109, USA. Electronic address: svenneti@med.umich.edu.
University of Michigan–Ann Arbor · USDana-Farber Cancer Institute · USChildren's Hospital of Philadelphia · USClinica Universidad de Navarra · ESChildren's National · USDiscovery Institute · USHospital for Sick Children · CAIcahn School of Medicine at Mount Sinai · USStanford University · USUniversity of California, San Francisco · USUniversity of Newcastle Australia · AUAdvocate Children's Hospital · USBaylor College of Medicine · USChildren's Mercy Hospital · USCincinnati Children's Hospital Medical Center · USColumbia University Irving Medical Center · USCornell University · USDaegu Gyeongbuk Institute of Science and Technology · KRDuke University · USInstitute of Cancer Research · GB
Funding
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3MPreclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0MTargeting integrated metabolic and epigenetic pathways in childhood ependymomasR01CA261926 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Deepak Nagrath, Benita Tamrazi · 2022 to 2026
$3.0MUnravelling metabolic dependencies in H3K27M mutant DIPGR01NS110572 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sriram Venneti · 2019 to 2026
$2.7MTargeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancerR01CA240515 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORGAN, MEREDITH A · 2020 to 2024
$2.2MTargeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline gliomaR01NS124607 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Carl J Koschmann · 2022 to 2026
$2.2MThe role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade gliomaR01NS119231 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOSCHMANN, CARL J · 2021 to 2025
$1.9MMECHANISMS OF POL II ELONGATION IN DIFFUSE MIDLINE GLIOMAR01NS129860 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI Jamie N. Anastas · 2023 to 2026
$1.8MTargeting metabolic dependencies in ZFTA-RELA fusion childhood ependymomasR01NS127799 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sriram Venneti · 2023 to 2026
$1.8MDeciphering non-canonical translation in high risk medulloblastomaK08CA263552 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Prensner · 2022 to 2026
$1.2MDefining Tumor Microenvironmental Interactions that drive THY1-Mediated Treatment Resistance in GlioblastomaK08NS128271 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Wajd Al-Holou · 2024 to 2026
$700kCancer Research UK 11736Cancer Research UK 13982Cancer Research UK 23536NCI NIH HHS K08 CA263552NCI NIH HHS R01 CA240515NCI NIH HHS R01 CA261926NIGMS NIH HHS T32 GM007863NINDS NIH HHS K08 NS128271NINDS NIH HHS R01 NS110572NINDS NIH HHS R01 NS119231NINDS NIH HHS R01 NS124607NINDS NIH HHS R01 NS127799NINDS NIH HHS R35 NS105068
Abstract
Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3) streamlining clinical efforts including biopsy, CNS-drug delivery, endpoint determination, and response monitoring. We highlight the importance of comprehensive collaboration to advance the understanding, diagnostics, and therapeutics for DMGs.
Indexed as
Brain NeoplasmsGliomaBiopsyBrainChildHumansMutation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.